Ark receives Finnish grant
The funding will be used to further develop Ark’s lentiviral vector production technology using baculoviruses (Baculo-lentiviral) to achieve required scale and GMP quality for clinical use. Additionally, Ark
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.